Rexin‑G®, a tumor‑targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Kim,Seth; Federman,Noah; Gordon,Erlinda M.; Hall,Frederick L.; Chawla,Sant P.

doi:10.3892/mco.2017.1231

Rexin‑G®, a tumor‑targeted retrovector for malignant peripheral nerve sheath tumor: A case report

Authors:
- Seth Kim
- Noah Federman
- Erlinda M. Gordon
- Frederick L. Hall
- Sant P. Chawla
View Affiliations

Affiliations: Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA 90403, USA, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Mattel Children's Hospital at UCLA, Los Angeles, CA 90095, USA, Counterpoint Biomedica LLC, Santa Monica, CA 90403, USA
Published online on: April 28, 2017 https://doi.org/10.3892/mco.2017.1231
Pages: 861-865
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Soft tissue sarcoma is a rare neoplasm of mesenchymal origin, accounting for only ~1% of all adult cancers and consisting of 75 histological subtypes. In the present report, the unique case of a 14 year‑old female with metastatic malignant peripheral nerve sheath tumor (formerly, malignant melanotic schwannoma) of the parotid gland, who experienced a durable response and sustained tumor control with Rexin‑G®, a tumor‑targeted retroviral expression vector encoding an anti‑cyclin G1 construct, is described. Post‑parotidectomy, and prior to the administration of Rexin‑G®, the patient received various chemotherapy regimens, including doxorubicin, ifosfamide, temozolomide, sorafenib, and an immunological therapy with interleukin‑2, which only resulted in the further progression of lung metastases. The patient subsequently participated in a Phase 1/2 gene therapy study, during which she received intravenous Rexin‑G® as monotherapy for two years with minimal drug‑associated adverse events. Currently, the patient has no evidence of active disease 9 years after commencing the Rexin‑G® treatment, and with no additional anti‑cancer therapy. In conclusion, Rexin‑G® may be a viable therapeutic option for malignant peripheral nerve sheath tumors, and should be further investigated in prospective histology‑specific clinical trials for this type, and possibly other types, of chemotherapy‑resistant sarcoma.

View Figures

View References

1	Vallat-Decouvelaere AV, Wassef M, Lot G, Catala M, Moussalam M, Caruel N and Mikol J: Spinal melanotic schwannoma: A tumour with poor prognosis. Histopathology. 35:558–566. 1999. View Article : Google Scholar : PubMed/NCBI
2	Rodriguez FJ, Folpe AL, Giannini C and Perry A: Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. Acta Neuropathol. 123:295–319. 2012. View Article : Google Scholar : PubMed/NCBI
3	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chawla SP, Chawla NS, Quon D, Chua-Alcala V, Blackwelder WC, Hall FL and Gordon EM: An advanced phase 1/2 study using an XC-targeted gene therapy vector for chemotherapy resistant sarcoma. Sarcoma Res Int. 3:10242016.
5	Gordon EM, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L and Hall FL: First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol. 24:177–185. 2004.PubMed/NCBI
6	Er U, Kazanci A, Eyriparmak T, Yigitkanli K and Senveli E: Melanotic schwannoma. J Clin Neurosci. 14:676–678. 2007. View Article : Google Scholar : PubMed/NCBI
7	Kurtkaya-Yapicier O, Scheithauer B and Woodruff JM: The pathobiologic spectrum of Schwannomas. Histol Histopathol. 18:925–934. 2003.PubMed/NCBI
8	Welling LC, Guirado VM, Tessari M, Felix AR, Zanellato C, Figueiredo EG, Taricco MA and Teixeira MJ: Spinal melanotic schwannomas. Arq Neuropsiquiatr. 70:156–157. 2012. View Article : Google Scholar : PubMed/NCBI
9	Faria MH, Dória-Netto RH, Osugue GJ, Lde S Queiroz and Chaddad-Neto FE: Melanotic schwannoma of the cervical spine progressing with pulmonary metastasis: Case report. Neurol Med Chir (Tokyo). 53:712–716. 2013. View Article : Google Scholar : PubMed/NCBI
10	Pan SY, Cheng YC and Kao TH: Intramedullary melanotic schwannoma: Case report and review of the literature. Surg Neurol Int. 5 Suppl 4:S181–S184. 2014. View Article : Google Scholar
11	Khoo M, Pressney I, Hargunani R and Tirabosco R: Melanotic schwannoma: An 11-year case series. Skeletal Radiol. 45:29–34. 2016. View Article : Google Scholar : PubMed/NCBI
12	Torres-Mora J, Dry S, Li X, Binder S, Amin M and Folpe AL: Malignant melanotic schwannian tumor: A clinicopathologic, immunohistochemical, and gene expression profiling study of 40 cases, with a proposal for the reclassification of ‘melanotic schwannoma’. Am J Surg Pathol. 38:94–105. 2014. View Article : Google Scholar : PubMed/NCBI
13	Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DT, Bewerunge-Hudler M, et al: Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 131:877–887. 2016. View Article : Google Scholar : PubMed/NCBI
14	Küsters-Vandevelde HV, van Engen-van Grunsven IA, Küsters B, van Dijk MR, Groenen PJ, Wesseling P and Blokx WA: Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol. 120:755–764. 2010. View Article : Google Scholar : PubMed/NCBI
15	Huang HY, Park N, Erlandson RA and Antonescu CR: Immunohistochemical and ultrastructural comparative study of external lamina structure in 31 cases of cellular, classical, and melanotic schwannomas. Appl Immunohistochem Mol Morphol. 12:50–58. 2004. View Article : Google Scholar : PubMed/NCBI
16	Killeen RM, Davy CL and Bauserman SC: Melanocytic schwannoma. Cancer. 62:174–183. 1988. View Article : Google Scholar : PubMed/NCBI
17	Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW and Gordon EM: Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Hum Gene Ther. 11:983–993. 2000. View Article : Google Scholar : PubMed/NCBI
18	Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM and Hall FL: Advanced phase I/II studies of targeted gene delivery in vivo: Intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Mol Ther. 18:435–441. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB and Hall FL: Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. Int J Oncol. 33:665–675. 2008.PubMed/NCBI
20	Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC III, Levy JP, Reed RA, Liu L, Bruckner HW and Hall FL: Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: Three-year clinical experience. Int J Oncol. 29:1053–1064. 2006.PubMed/NCBI
21	Gordon EM and Hall FL: Rexin-G, a targeted genetic medicine for cancer. Expert Opin Biol Ther. 10:819–832. 2010. View Article : Google Scholar : PubMed/NCBI